Institutional Equity Research for Undercovered Public Companies
Alliance Equity Research publishes independent and company-sponsored research on undercovered, emerging, and high-potential public companies globally.
Search AER-covered companies and Insights, or explore listed companies across global markets.
Latest Research
Recent initiation reports, research updates and company commentary from Alliance Equity Research.
ASML Holding N.V.
ASML
A Near-Monopoly Lithography Franchise Powering Global Semiconductor Supply Chain with EUV Dominance and High-NA Optionality
Initiation coverage examining EUV leadership, High-NA optionality, DUV economics, installed-base services, competitive moat, semiconductor demand drivers, valuation summary, and key risks.
Dexcom, Inc.
DXCM
Dominant CGM Franchise Leveraging Technology, Coverage Expansion, and Consumer Tailwinds to Sustain Multi-Year Growth
Initiation coverage examining CGM market leadership, product strategy, reimbursement expansion, recurring sensor economics, international growth, valuation summary, and key risks.
Insights
Timely analysis of company developments, industry trends, capital markets activity, and emerging investment themes across global public markets.
Mining & Critical MineralsLifezone’s Kabanga Project Needs Near-Term Funding as Orion Investment Talks Advance
Lifezone Metals is negotiating a potential investment in its Kabanga nickel project while seeking additional capital for its near-term activities. The company says it needs funding by February 2027 to support its operations and maintain a loan covenant. Kabanga’s feasibility study envisages an underground mine and concentrator in Tanzania, with $942 million in estimated pre-production capital. The terms of the Tanzanian government agreement, project financing and any outside investment will determine how the project advances and how much of its future economics Lifezone retains.
Biotechnology & HealthcarePTC’s Sephience Launch Lifts Sales as Milestone Payments and Acquisitions Shape Cash Flow
PTC Therapeutics’ Sephience launch is driving rapid product revenue growth, with more than 2,000 patients receiving the phenylketonuria treatment worldwide at the end of September. The company has raised its annual product sales outlook and acquired an experimental gene therapy for Fabry disease. The financial picture is more complex than the revenue growth alone: Sephience’s success has triggered acquisition-related payments, and royalties reported from another medicine have already been sold. Continued patient access and the cost of expanding PTC’s portfolio will determine how much cash the business retains.
Technology & SemiconductorsAXT’s Wafer Sales Surge as Subsidiary Financing Adds Capacity and Shares Future Earnings
AXT’s third-quarter sales more than doubled from a year earlier as demand for indium phosphide wafers used in optical communications accelerated. Higher volumes and a richer product mix helped lift gross margin to 56%. The company is expanding capacity through its Chinese subsidiary Tongmei, where a proposed outside investment would bring in capital but reduce AXT’s ownership. Export permits, the timing of customer deliveries and the terms attached to subsidiary funding will influence how much of the manufacturing growth ultimately benefits AXT shareholders.
Mining & Critical MineralsAsante Gold Needs New Funding as Bibiani’s Recovery Takes Shape
Asante Gold has until November 30 to secure at least $100 million in new funding under an agreement with its lenders. As the company negotiates, its mines must generate enough cash to support investment and financing costs. Higher-grade ore at Bibiani could improve production, but the recovery depends on execution and the terms of the financing.
Industrials & AerospaceMinerals Technologies’ Sales Growth Outruns Earnings as Pricing Recovery Remains Incomplete
Minerals Technologies’ industrial products are growing, but higher costs and delayed contract-price adjustments have reduced consumer-business margins. Its latest results make pricing recovery central to near-term earnings improvement. New calcium-metal and steel-waste technologies offer additional markets, with commercial development still at an early stage. Cash generation has strengthened, while proposed funding for legacy talc claims remains substantial. October’s refinancing extends debt maturity at a higher interest cost. The existing businesses’ profitability will determine how much cash the company can generate while developing those opportunities and addressing its obligations.
Industrials & AerospaceSensient’s Color Growth Raises Earnings as Natural-Color Expansion Absorbs More Cash
Sensient’s Color Group increased third-quarter sales 18.1% and operating profit 22.0% as food manufacturers reformulated products. Its formulation expertise and botanical supply network support natural-color adoption, while inventory and factory expansion are increasing cash requirements. Across the company, nine-month operating cash flow fell below capital expenditure, and borrowing increased. Color’s stronger margins demonstrate an earnings contribution from higher volumes. The expansion’s financial progress will depend on maintaining that profitability as new capacity enters service and converting more sales into cash to support continued investment.
Mining & Critical MineralsUS Lime’s Texas Kiln Nears Commissioning as Higher Costs Offset Revenue Growth
United States Lime & Minerals increased third-quarter revenue through higher prices and shipment volumes, while diesel costs and startup inefficiencies at its new Texas kiln reduced profit. Management expects final commissioning in the fourth quarter, when depreciation on the new equipment will begin. The company has ample cash to complete the project, but construction delays and early signs of slower Texas housing could limit demand for its output. Earnings improvement will require reliable production, lower unit costs and sufficient sales to earn a return on the investment.
Biotechnology & HealthcareINOVIO’s Voceryq Approval Shifts Attention to Patient Uptake, Competition and Launch Funding
INOVIO’s first approved DNA medicine offers a new approach to reducing airway surgery. Commercial adoption will depend on its treatment profile, reimbursement and competition, while management’s disclosed cash runway overlaps the planned launch quarter and continuing clinical obligations extend beyond it.
Explore Coverage
AER-covered companies combine public-company information with our proprietary research, updates, and commentary.
Find AER-Covered Companies
Explore AER-covered companies by sector, region, and market capitalization.
Research Built Around the Model
Alliance Equity Research develops written company analysis and detailed financial models together. The model is used to test operating assumptions, financial outcomes, scenarios, and valuation frameworks.
- Fundamental company analysis
- Integrated financial modeling
- Scenario-based valuation framework
- Ongoing coverage after initiation
Operating Drivers
RevenuePricingVolumeKPIsFinancial Forecast
Illustrative forecast structure, without financial values Metric FY1 FY2 FY3 FY4 Revenue Forecast output placeholder Forecast output placeholder Forecast output placeholder Forecast output placeholder EBITDA Forecast output placeholder Forecast output placeholder Forecast output placeholder Forecast output placeholder FCF Forecast output placeholder Forecast output placeholder Forecast output placeholder Forecast output placeholder Scenarios & Sensitivities
BaseUpsideDownsideValuation
DCF · Trading Multiples
Published Research
Is Your Company Undercovered?
Alliance Equity Research works with listed companies, recently listed companies, and businesses preparing to list, with a focus on undercovered, emerging, and high-potential opportunities. Our coverage includes initiation research, detailed financial modeling, and ongoing research updates.
- Initiation Research
- Financial Model
- Ongoing Updates
Investor Discovery
- AER Website
- FactSet
- LSEG Refinitiv
- AlphaSense
- Distribution Partners
Stay Current with AER
Choose the research and Insights updates you want to receive.